To provide neuro-oncologists and radiation oncologists with up-to-date information on central nervous system malignancies.
This activity is designed for neuro-oncologists and radiation oncologists. No prerequisites required.
At the conclusion of this activity, the participant should be able to:
- Discuss the latest trends in diagnosing central nervous system (CNS) malignancies.
- Identify how various factors affect the prognosis of CNS malignancies.
- Evaluate novel treatment strategies and emerging agents for the management of gliomas.
- Differentiate among and apply the least invasive techniques for re-irradiation of gliomas.
- Describe the heterogeneity within tumor types and the key factors to consider when developing treatment plans tailored to individual patients.
- Incorporate information and conclusions from recent clinical trials into daily clinical practice, especially the management of gliomas.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Estimated time to complete activity: 1 hour
After reading this monograph, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.
Release date: July 15, 2008. Expiration date: July 15, 2010.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
This program is supported by an educational grant from Schering-Plough.